Samira Shaikhly Sells 5,935 Shares of Septerna (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 5,935 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $28.93, for a total transaction of $171,699.55. Following the transaction, the insider owned 793 shares in the company, valued at approximately $22,941.49. This trade represents a 88.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Samira Shaikhly also recently made the following trade(s):

• On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88.

Septerna Stock Up 2.7%

Shares of Septerna stock opened at $31.37 on Friday. Septerna, Inc. has a 52-week low of $9.70 and a 52-week high of $32.63. The company’s 50-day simple moving average is $26.01 and its 200-day simple moving average is $26.44. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -38.73 and a beta of 2.39.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The business had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. Equities research analysts anticipate that Septerna, Inc. will post -1.57 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SEPN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Tuesday, April 21st. Cantor Fitzgerald restated an “overweight” rating and set a $60.00 target price on shares of Septerna in a research report on Tuesday, March 10th. Truist Financial upped their target price on shares of Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Wall Street Zen lowered shares of Septerna from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Zacks Research upgraded shares of Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Septerna has a consensus rating of “Moderate Buy” and a consensus target price of $43.13.

Institutional Trading of Septerna

Large investors have recently modified their holdings of the business. Group One Trading LLC grew its position in shares of Septerna by 111.8% in the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after purchasing an additional 8,955 shares during the last quarter. Global Retirement Partners LLC acquired a new stake in shares of Septerna in the fourth quarter valued at approximately $35,000. Russell Investments Group Ltd. acquired a new stake in shares of Septerna in the third quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Septerna in the fourth quarter valued at approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Septerna in the fourth quarter valued at approximately $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.